Page last updated: 2024-12-06

biphenyl-2-carboxylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Biphenyl-2-carboxylic acid is an organic compound with the formula C13H10O2. It is a white solid that is soluble in organic solvents. Biphenyl-2-carboxylic acid has been used in the synthesis of various pharmaceutical compounds, including anti-inflammatory drugs and anti-cancer agents. The compound has also been investigated for its potential use in the development of new materials, such as polymers and coatings. The study of biphenyl-2-carboxylic acid is important because of its potential applications in various fields. Its synthesis is typically achieved through the reaction of biphenyl with carbon dioxide in the presence of a catalyst. Researchers have studied biphenyl-2-carboxylic acid for its biological activity, particularly its potential anti-inflammatory and anti-cancer effects. It is also of interest due to its potential for use in the development of new materials with improved properties. '

biphenyl-2-carboxylic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID70357
CHEMBL ID3092388
SCHEMBL ID133057
MeSH IDM0293298

Synonyms (53)

Synonym
AC-3069
BB 0216400
1,1'-biphenyl-2-carboxylic acid
(1,1'-biphenyl)carboxylic acid
biphenylcarboxylic acid
2-biphenylcarboxylic acid
o-phenylbenzoic acid
diphenyl-2-carboxylic acid
947-84-2
nsc76051
[1,1'-biphenyl]-2-carboxylic acid
nsc-76051
2-phenylbenzoic acid
biphenyl-2-carboxylic acid, 98%
STK026406
biphenyl-2-carboxylic acid
inchi=1/c13h10o2/c14-13(15)12-9-5-4-8-11(12)10-6-2-1-3-7-10/h1-9h,(h,14,15)
ilysakhoybpspc-uhfffaoysa-
KUC107406N
ksc-20-075
P0906
AKOS000120801
nsc 76051
einecs 213-432-1
51317-27-2
FT-0613324
AM20060758
CHEMBL3092388 ,
AB01325741-02
SCHEMBL133057
SY003735
mfcd00002463
phenylbenzoic acid
2-phenyl benzoic acid
biphenyl carboxylic acid
2-phenyl-benzoic acid
1,1'-biphenylcarboxylic acid
W-100184
STR08660
TS-02802
biphenylcarboxylic acid-(2)
1,1'-biphenyl, 2-carboxylic acid
F2173-1248
CS-W001937
2-biphenylcarboxylic acid, pract.
NCGC00332644-01
DTXSID30870814
2-biphenylcarboxylic acid o-phenylbenzoic acid
A850878
bdbm50533338
EN300-20886
HY-W001937
Z104484440
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Polyphenol oxidase 2Agaricus bisporusIC50 (µMol)1,000.00000.03403.987110.0000AID1628074; AID1628075
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Platelet glycoprotein VIHomo sapiens (human)Kd1,500.00000.04110.04110.0411AID1692279
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
positive regulation of platelet aggregationPlatelet glycoprotein VIHomo sapiens (human)
enzyme-linked receptor protein signaling pathwayPlatelet glycoprotein VIHomo sapiens (human)
platelet activationPlatelet glycoprotein VIHomo sapiens (human)
collagen-activated tyrosine kinase receptor signaling pathwayPlatelet glycoprotein VIHomo sapiens (human)
collagen-activated signaling pathwayPlatelet glycoprotein VIHomo sapiens (human)
platelet aggregationPlatelet glycoprotein VIHomo sapiens (human)
immune response-regulating signaling pathwayPlatelet glycoprotein VIHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
transmembrane signaling receptor activityPlatelet glycoprotein VIHomo sapiens (human)
protein bindingPlatelet glycoprotein VIHomo sapiens (human)
collagen bindingPlatelet glycoprotein VIHomo sapiens (human)
signaling receptor activityPlatelet glycoprotein VIHomo sapiens (human)
collagen receptor activityPlatelet glycoprotein VIHomo sapiens (human)
protein tyrosine kinase bindingPlatelet glycoprotein VIHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
membrane raftPlatelet glycoprotein VIHomo sapiens (human)
plasma membranePlatelet glycoprotein VIHomo sapiens (human)
cell surfacePlatelet glycoprotein VIHomo sapiens (human)
extracellular exosomePlatelet glycoprotein VIHomo sapiens (human)
tetraspanin-enriched microdomainPlatelet glycoprotein VIHomo sapiens (human)
plasma membranePlatelet glycoprotein VIHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1628075Inhibition of mushroom tyrosinase diphenolase activity using L-DOPA as substrate measured every 30 s for 25 times2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Discovery of a new type of scaffold for the creation of novel tyrosinase inhibitors.
AID1467145Inhibition of mushroom tyrosinase using L-tyrosinase as substrate measured at 60 secs interval for 25 times2017Bioorganic & medicinal chemistry letters, 07-01, Volume: 27, Issue:13
Structural insight into the active site of mushroom tyrosinase using phenylbenzoic acid derivatives.
AID1059430Inhibition of recombinant human IDO1 expressed in Escherichia coli EC538 using L-tryptophan as substrate at 1 mM after 1 hr relative to control2013Bioorganic & medicinal chemistry, Dec-15, Volume: 21, Issue:24
Discovery and characterisation of hydrazines as inhibitors of the immune suppressive enzyme, indoleamine 2,3-dioxygenase 1 (IDO1).
AID1628074Inhibition of mushroom tyrosinase monophenolase activity using L-tyrosine as substrate measured every 60 s for 25 times2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
Discovery of a new type of scaffold for the creation of novel tyrosinase inhibitors.
AID1486518Inhibition of acid-induced wild type transthyretin (unknown origin) aggregation expressed in Escherichia coli pre-incubated for 30 mins before acid addition and further incubated for 72 hrs at 37 degC under dark conditions by UV-Vis spectrophotometry2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID1486519Binding affinity to transthyretin in human blood plasma assessed as plasma binding selectivity by measuring stoichiometry of small molecule bound to TTR incubated for 24 hrs at 37 degC by RP-HPLC2017Bioorganic & medicinal chemistry letters, 08-01, Volume: 27, Issue:15
Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
AID1692279Binding affinity to recombinant GP6 (unknown origin) at protein to compound ratio of 1 : 1 to 1 : 10 by 2D 15N-1H TROSY-HSQC NMR spectroscopy2020Journal of medicinal chemistry, 11-12, Volume: 63, Issue:21
Progress toward a Glycoprotein VI Modulator for the Treatment of Thrombosis.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (16.67)18.2507
2000's0 (0.00)29.6817
2010's4 (66.67)24.3611
2020's1 (16.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.74

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.74 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.32 (4.65)
Search Engine Demand Index22.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.74)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]